Tango Therapeutics reports 82% response rate for chemo-free pancreatic cancer combo at ESMO

Key points

• Tango Therapeutics reported an 82% tumor response rate for a combination therapy involving its experimental drug and Revolution Medicines’ Rasonque in advanced pancreatic cancer patients.
• The trial data, presented at ESMO in Madrid, showed that 88% of patients were alive without tumor progression at the nine-month assessment.
• The regimen is notable for excluding chemotherapy, which has traditionally been the standard of care for this aggressive cancer type.
• The results reinforce the theory that combining targeted drugs may provide greater clinical benefit than using single agents for pancreatic cancer.

Background

Recent developments in pancreatic cancer treatment have focused on overcoming the disease's historical resistance to therapy. In October 2026, Verastem Oncology reported promising early data for an oral KRAS inhibitor in pancreatic and lung cancer trials, while a study in Nature Genetics identified MYC gene amplification as a driver of immune evasion in pancreatic ductal adenocarcinoma. These advancements highlight a broader industry shift toward targeted and precision medicine approaches for a cancer that previously relied heavily on chemotherapy.

How outlets are covering it

STAT emphasized the clinical significance of the chemo-free regimen and the durability of the response, framing the data as a validation of the combination therapy model. Endpoints News highlighted the result as a key milestone for Tango, noting that the data met expectations for the Rasonque partnership, though the full details were behind a paywall. Both outlets agreed on the positive implications for targeted therapy in pancreatic cancer, but STAT focused more on the broader therapeutic paradigm shift, while Endpoints focused on the specific commercial and partnership implications for the involved companies.

Why it matters

The results suggest a potential shift away from chemotherapy as the primary treatment for advanced pancreatic cancer, offering patients a regimen with high response rates and durability. This could improve survival outcomes and quality of life for a disease with a notoriously poor prognosis. The success of this combination also validates the strategy of pairing targeted drugs, which may influence future trial designs and investment in the sector.

What to watch

Tango Therapeutics and Revolution Medicines will likely use these data to support regulatory submissions or advance the combination into later-stage trials. The industry will watch for similar combination strategies in other aggressive cancers. Investors may reassess the valuation of companies involved in targeted pancreatic cancer therapies, particularly those with partnerships in this space.